AMRX
Amneal Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
17.27
close · 2026-08-13
value
36
cheaper than peers36
quality
68
stronger fundamentals68
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
34 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 1.89× | 66 |
| EV to EBITDA | 12.62× | 56 |
| forward P/E | 14.60× | 43 |
| price to book | 167.67× | 2 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 613.0% | 98 |
| operating margin | 18.4% | 78 |
| revenue growth | 9.9% | 58 |
| debt to equity | 2386.5% | 2 |
4 of 4 measures available
Facts
| market cap | $6B |
| free cash flow | -$115.7M |
| employees | 8,700 |
| first trade | 2018-05-07 |
| next earnings | 2026-07-30 |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 0.22 | -0.38 | -0.48 | -0.86 |
| free cash flow | $225.6M | $220.1M | $276.4M | -$25.5M |
| net income | $72.1M | -$116.9M | -$84.0M | -$130.0M |
| revenue | $3.02B | $2.79B | $2.39B | $2.21B |
| unusual items | -$2.8M | -$156.6M | -$35.8M | -$296.8M |